8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
May 1, 2026·SEC
FibroBiologics, Inc. Common Stock(FBLG)Earnings, Financials & Key Ratios
FBLG•NASDAQ
Price updated Jun 19, 2026
AboutFibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$16M-20.2%
- Net Income-$19M-67.1%
- EPS (Diluted)-8.40-23.5%
- ROE-419.44%+25.1%
FBLG Key Insights
FibroBiologics, Inc. Common Stock (FBLG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Profits declining 74.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 35.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when FBLG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FBLG Price & Volume
FibroBiologics, Inc. Common Stock (FBLG) stock price & volume — 10-year historical chart
Loading chart...
FBLG Growth Metrics
FibroBiologics, Inc. Common Stock (FBLG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-143.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-96.56%
Return on Capital
10 Years-1516.14%
5 Years-1516.14%
3 Years-1763.31%
Last Year-287.57%
FBLG Recent Earnings
FibroBiologics, Inc. Common Stock (FBLG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (43%)
Q1 2026Latest
Feb 24, 2026Metric
Actual
Est
EPS
$0.98+31.9%
$1.44
Rev
—
—
Q4 2025
Oct 31, 2025Metric
Actual
Est
EPS
$0.13-30.0%
$0.10
Rev
—
—
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.12-9.1%
$0.11
Rev
—
—
Q2 2025
Mar 31, 2025Metric
Actual
Est
EPS
$0.09+10.0%
$0.10
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.98vs $1.44+31.9% | — |
| Q4 2025 | Oct 31, 2025 | $0.13vs $0.10-30.0% | — |
| Q3 2025 | Jul 31, 2025 | $0.12vs $0.11-9.1% | — |
| Q2 2025 | Mar 31, 2025 | $0.09vs $0.10+10.0% | — |
Based on last 12 quarters of dataView full earnings history →
FBLG Peer Comparison
FibroBiologics, Inc. Common Stock (FBLG) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MESO | 1.85B | 14.37 | -17.11 | 191.39% | -5.94% | -17.1% | 0.21 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CELC | 4.28B | 87.76 | -23.22 | -244.61% | 1.94 | |||
 VCEL | 2.05B | 40.10 | 125.31 | 16.45% | 7.35% | 6.41% | 0.28 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare FBLG vs Peers
FibroBiologics, Inc. Common Stock (FBLG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FBLG Income Statement
FibroBiologics, Inc. Common Stock (FBLG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 832K | 234K |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -832K▲ 0% | -234K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - |
Operating Expenses | 1.17M | 1.58M | 4.47M | 8.89M | 13.74M | 15.82M | 16.95M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 500K | 1.06M | 3.32M | 6.52M | 9.23M | 9.24M | 8.61M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 669K | 521K | 1.15M | 2.37M | 4.5M | 7.41M | 8.58M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -832K | -234K |
Operating Income | -1.17M▲ 0% | -1.58M▼ 35.0% | -4.47M▼ 183.1% | -8.89M▼ 99.0% | -13.74M▼ 54.5% | -16.65M▼ 21.2% | -17.19M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -34.99% | -183.08% | -98.99% | -54.54% | -21.2% | - |
EBITDA | 0 | -1.58M | -4.37M | -8.45M | -13.16M | -15.82M | -16.28M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -177.12% | -93.28% | -55.75% | -20.15% | -14.46% |
D&A (Non-Cash Add-back) | 1.17M | 0 | 94K | 437K | 573K | 832K | 908K |
EBIT | -1.17M | -1.58M | -4.47M | -16.34M | -11.14M | -18.44M | -18.47M |
Net Interest Income | 0 | -4K | -654K | -147K | 231K | 43K | -40K |
Interest Income | 0 | 0 | 0 | 0 | 251K | 247K | 168K |
Interest Expense | 0 | 4K | 654K | 147K | 20K | 204K | 208K |
Other Income/Expense | 0 | -4K | -654K | -7.6M | 2.58M | -2M | -1.49M |
Pretax Income | -1.17M▲ 0% | -1.58M▼ 35.3% | -5.12M▼ 223.7% | -16.48M▼ 221.9% | -11.16M▲ 32.3% | -18.65M▼ 67.1% | -18.68M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.17M▲ 0% | -1.58M▼ 35.3% | -5.12M▼ 223.7% | -16.48M▼ 221.9% | -11.16M▲ 32.3% | -18.65M▼ 67.1% | -18.68M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -35.33% | -223.7% | -221.91% | 32.3% | -67.06% | -143.64% |
Net Income (Continuing) | -1.17M | -1.58M | -5.12M | -16.48M | -11.16M | -18.65M | -18.68M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.72▲ 0% | -0.97▼ 35.3% | -3.20▼ 228.5% | -11.80▼ 268.8% | -6.80▲ 42.4% | -8.40▼ 23.5% | -8.37▲ 0% |
EPS Growth % | - | -35.28% | -228.54% | -268.75% | 42.37% | -23.53% | -96.56% |
EPS (Basic) | -0.72 | -0.97 | -3.20 | -11.80 | -6.80 | -8.40 | - |
Diluted Shares Outstanding | 1.62M | 1.62M | 1.62M | 1.62M | 1.64M | 2.23M | 2.23M |
Basic Shares Outstanding | 1.62M | 1.62M | 1.62M | 1.62M | 1.64M | 2.23M | 2.23M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
FBLG Balance Sheet
FibroBiologics, Inc. Common Stock (FBLG) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 0 | 468K | 2.63M | 9.21M | 14.23M | 6.35M | 2.9M |
Cash & Short-Term Investments | 0 | 407K | 2.27M | 9.16M | 13.98M | 4.89M | 1.48M |
Cash Only | 0 | 407K | 2.27M | 9.16M | 13.98M | 4.89M | 1.48M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 300K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 24K | 30K | 16K | 18K | 1.46M | 1.42M |
Total Non-Current Assets | 0 | 0 | 2.2M | 2.61M | 2.22M | 3.27M | 3.03M |
Property, Plant & Equipment | 0 | 0 | 2.2M | 2.61M | 2.22M | 3.22M | 2.98M |
Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 48K | 48K |
Total Assets | 0▲ 0% | 468K▲ 0% | 4.82M▲ 930.8% | 11.82M▲ 145.0% | 16.45M▲ 39.1% | 9.62M▼ 41.5% | 5.94M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | - | 930.77% | 145.05% | 39.12% | -41.51% | -49.97% |
Total Current Liabilities | 0 | 1.76M | 7.07M | 9.18M | 12.73M | 1.76M | 1.83M |
Accounts Payable | 0 | 233K | 493K | 1.44M | 2.7M | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 1.3M | 5.45M | 0 | 9.17M | 706K | 723K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 803K | 7.24M | 460K | 1.05M | 1.11M |
Current Ratio | - | 0.27x | 0.37x | 1.00x | 1.12x | 3.61x | 1.59x |
Quick Ratio | - | 0.27x | 0.37x | 1.00x | 1.12x | 3.61x | 1.59x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 1.75M | 1.39M | 984K | 1.7M | 1.51M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.7M | 1.51M |
Capital Lease Obligations | 0 | 0 | 1.75M | 1.39M | 984K | 0 | 2.08M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 0 | 1.76M | 8.82M | 10.57M | 13.71M | 3.46M | 3.34M |
Total Debt | 0 | 1.3M | 7.52M | 1.75M | 10.55M | 2.41M | 2.23M |
Net Debt | 0 | 893K | 5.26M | -7.42M | -3.43M | -2.48M | 750K |
Debt / Equity | - | - | - | 1.39x | 3.86x | 0.39x | 0.86x |
Debt / EBITDA | - | - | - | - | - | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | - | -0.05x |
Interest Coverage | - | -394.50x | -6.83x | -111.14x | -557.05x | -90.40x | -88.81x |
Total Equity | 0▲ 0% | -1.29M▲ 0% | -4M▼ 209.8% | 1.25M▲ 131.4% | 2.73M▲ 118.3% | 6.16M▲ 125.1% | 2.6M▲ 0% |
Equity Growth % | - | - | -209.77% | 131.36% | 118.28% | 125.08% | 176.32% |
Book Value per Share | - | -0.79 | -2.46 | 0.77 | 1.66 | 2.76 | 1.16 |
Total Shareholders' Equity | 0 | -1.29M | -4M | 1.25M | 2.73M | 6.16M | 2.6M |
Common Stock | 1.17M | 0 | 1K | 1K | 0 | 1K | 1K |
Retained Earnings | -1.17M | -2.75M | -7.87M | -24.36M | -35.52M | -54.16M | -59.16M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 1.46M | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FBLG Cash Flow Statement
FibroBiologics, Inc. Common Stock (FBLG) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -1.17M | -1.41M | -4.07M | -6.4M | -11.9M | -16.39M | -15.48M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -20.62% | -188.37% | -57.43% | -85.92% | -37.75% | -142.7% |
Net Income | -1.17M | -1.58M | -5.12M | -16.48M | -11.16M | -18.65M | -18.68M |
Depreciation & Amortization | 0 | 0 | 94K | 437K | 573K | 832K | 908K |
Stock-Based Compensation | 0 | 0 | 265K | 1.76M | 2.22M | 2.69M | 2.83M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 0 | 389K | 7.39M | -4.09M | 2.05M | 1.46M |
Working Capital Changes | 0 | 172K | 307K | 493K | 559K | -3.31M | -2M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 525K | 671K | 1.25M | 0 | 289K |
Cash from Investing | 0 | 0 | 0 | -495K | -184K | -262K | -219K |
Capital Expenditures | 0 | 0 | 0 | -495K | -184K | -262K | -219K |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.17M | 1.82M | 5.92M | 13.79M | 16.91M | 7.57M | 8.52M |
Debt Issued (Net) | 0 | 1.52M | 3.77M | 300K | 9.4M | 975K | 1.22M |
Equity Issued (Net) | 0 | 0 | 2.15M | 16.14M | 7.51M | 6.59M | 7.3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.17M | 292K | 0 | -2.65M | 0 | 0 | 0 |
Net Change in Cash | 0▲ 0% | 407K▲ 0% | 1.86M▲ 356.8% | 6.9M▲ 271.0% | 4.82M▼ 30.1% | -9.09M▼ 288.5% | -7.18M▲ 0% |
Free Cash Flow | -1.17M▲ 0% | -1.41M▼ 20.6% | -4.07M▼ 188.4% | -6.9M▼ 69.6% | -12.09M▼ 75.2% | -16.66M▼ 37.8% | -15.7M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -20.62% | -188.37% | -69.6% | -75.25% | -37.82% | -19.68% |
FCF per Share | -0.72 | -0.87 | -2.50 | -4.24 | -7.35 | -7.46 | -7.03 |
FCF Conversion (FCF/Net Income) | 1.00x | 0.89x | 0.79x | 0.39x | 1.07x | 0.88x | 0.84x |
Interest Paid | 0 | 0 | 0 | 2K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FBLG Key Ratios
FibroBiologics, Inc. Common Stock (FBLG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -1315.64% | -559.73% | -419.44% | -767.07% |
Return on Invested Capital (ROIC) | - | -774.62% | - | - | -839.45% | -423.16% |
Debt / Equity | - | - | 1.39x | 3.86x | 0.39x | 0.86x |
Interest Coverage | -394.50x | -6.83x | -111.14x | -557.05x | -90.40x | -88.81x |
FCF Conversion | 0.89x | 0.79x | 0.39x | 1.07x | 0.88x | 0.84x |
Related:FBLG Dividend History·FBLG Revenue History·FBLG Price History·FBLG P/E History·FBLG Financial Ratios·FBLG Institutional Holders
FBLG SEC Filings & Documents
FibroBiologics, Inc. Common Stock (FBLG) SEC filings — annual & quarterly reports (10-K, 10-Q)
FBLG Frequently Asked Questions
FibroBiologics, Inc. Common Stock (FBLG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
FibroBiologics, Inc. Common Stock (FBLG) grew revenue by 0.0% over the past year. Growth has been modest.
FibroBiologics, Inc. Common Stock (FBLG) reported a net loss of $18.7M for fiscal year 2025.
Dividend & Returns
FibroBiologics, Inc. Common Stock (FBLG) has a return on equity (ROE) of -419.4%. Negative ROE indicates the company is unprofitable.
FibroBiologics, Inc. Common Stock (FBLG) had negative free cash flow of $15.7M in fiscal year 2025, likely due to heavy capital investments.